Vaccine Scene 2001: Update and Overview

References: (Part 1, Part 2)

(1) Dublin L, Health Progress, 1935-1945, Metropolitan Life Insurance Company, 1948, page 12.

(2) Alderson M, International Mortality Statistics, (Washington D.C., Facts on File, 1981, pages 161-162, 164-165, 177-178, and 216.

(3) Morbidity and Mortality Weekly Report, July 30, 1999, 48:621-628.

(4) Diodati CJM, Immunization History, Ethics, Law and Health, Integral Aspects Incorporated, Windsor, Ontario, 1999, pages 104-106.

(5) Vaccination, 100 Years of Orthodox Research Shows that Vaccines Represent a Medical Assault on the Immune System, Vera Scheibner, Ph.D., 1993, pages 33-46, available from New Atlantean Press, PO Box 9638-925, Santa Fe, NM 87504.

(6) Stratton KR, CJ Howe, and RB Johnston, Jr., Editors, Adverse Events Associated with Childhood Vaccines; Evidence Bearing on Causality, Institute of Medicine, National Academy Press, Washington D.C., l994 pp. 211-236.

(7) Low AL, Electroencephalographic studies following Pertussis immunization, J Pediatrics, 1955;47:35-39.

(8) Eibl M et al, Abnormal T-lymphocyte subpopulations in healthy subjects after tetanus booster immunization, (letter), NEJM,1984;310(3):198-199.

(9) Nouno S et al, Adverse effects on EEG and clinical condition after immunizing children with convulsive disorders, Acta Paediatr Japan, Aug., 1990; 32(4):357-360.

(10) Immunologic findings in children with abnormal reactions after vaccination, Czechoslovakia Pediatrics, January, 1993; 48(1): pp. 9-12.

(11) Pabst HF et al, Kinetics of immunologic responses after primary MMR vaccination, Vaccine, 1997; 15(1):10-14.

(12) A Shot in the Dark, Harris L Coulter & Barbara Loe Fisher, Avery Publishing Group, Inc., Garden City Park, New York, 1991, page 47.

(13) Contact Dr. Andrea Valeri 01139-0535-26545, public section: phone-fax 0039-30-20.90.288 (Rosa Carla) Italy.

(14) Kerleau JM et al, La Vaccinazione anti-hepatite B e una nuova cause di vasculite necrotizzante? (lettera) Rev Med Interne, 1997;18(6):491-492.

(15) Cohen AD & Y Shoenfeld, Autoimmunita indoni dai vaccini, J Autoimmunity, Dec., 1996; 9(6):699-703.

(16) Disdier GB et al, Pccisopme de a vena centrale della retina dopo vaccinazione antihepatite B con vaccino recombinante, Presse Med,Feb. 1, 1997; 26(2):62-65.

(17) Cockwell P, Vasculitis related to hepatitis B vaccine, (letter),British Medical J, 1991; 301:1281.

(18) Niu MT et al, Neonatal deaths after hepatitis B vaccine, Arch Pediatr Adolesc Med, Dec., 1999; 153:1279-1282.

(19) Behan PO et al, Acute necrotizing encephalopathy, Post-Graduate Medicine,
Oct., l973; 54(4):154-160.

(20) Ribera EF, Polyneuropathy associated with administration of hepatitis B
Vaccine, New Engl J Med, Sept. 8, 1983; 309(10):614-615.

(21) Fried M et al, Uveitis after hepatitis B vaccine, Lancet , Sept.12, 1987; 2(8559):631-632.

(22) Shaw FE, Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination, Experience of the first three years, Amer J Epidemiol, Feb., l998; 127(2): 337-352.

(23) Biron P et al, Myasthenia gravis after general anesthesia and hepatitis B vaccine, Arch Int Med, Dec., 1998;148(12):2685.

(24) Goolsby PL, Erythema nodosum after recombined hepatitis B vaccine, New Engl J Med, Oct. 26, 1989;321(17):1198-1199.

(25) Herreolen L et al, Central-nervous-system demyelination after immunization with recombinant hepatitis B vaccine, Lancet, Nov. 9, 1991;338(8776):1174-1175.

(26) Nadler JP, Multiple sclerosis and hepatitis B vaccine, Clin Inf Dis, Nov., 1993;17(5):928-929.

(27) Kaplanski G et al, Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype, J Neurol Neurosurg Psychiatry,June, 1995; 58(6):758-759.

(28) Anonymous, Hepatitis B vaccines: reported reactions, World Health Organization Adverse Drug Reaction Bulletin, August, l990.

(29) Trevisani T et al, Transverse myelitis following hepatits B vaccination, J Hepatol, Sept., 1993;19(2):317-318.

(30) Brezin A, Visual loss and eosinophilia after recombinant hepatitis B vaccine, Lancet, Aug. 28, 1993;342:563-564.

(31) Vautier G, Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination, British J Rheumatol,Oct., 1994; 33(10):991.

(32) Hassan W, Reiters syndrome and reactive arthritis in health care workers after vaccination, Brit Med J, July 9, 1994;309:94.

(33) Wakefield AJ et al, Ileal-lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, Lancet,Feb. 28, 1998; 351:637-641.

(34) Institute of Medicine, (1991 (Adverse Effects of Pertussis and Rubella Vaccines, National Academy Press, Washington D.C.

(35) Terpstra OK et al, Comparison of vaccination of mice and rats with Hemophilus influenza and Bordetella pertussis as models, Clin Exp Pharmac Physiol, April, 1979; 6(2):139-149.

(36) Daum RS et al, Decline in serum antibody to the capsule of the Hemophilus influenza type b in the immediate post-immunization period, J Pediatrics, May, 1999; 114(5):742-747.

(37) Vaccination and Behavioral Disorders, (a review of a controversy), by Greg Wilson, Tuntable Creek Publishing, PO Box 1448, Lismore NSW 2480, Australia, 2000.

(38) Sheila Kaplan & Jim Morris, "Kids at risk," U.S. News & World Report, Cover Story 6/19/00.

(39) Cherry JD et al, Pertussis immunization and characteristics related to first seizures in infants and children, J Pediatrics, 1993;122(6):900-903.

(40) Camfield P, Brain damage from pertussis immunization, AIDC, 1992;146:327-331.

(41) Blumberg DA et al, Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying, Pediatrics, June, 1993;91(6):1158-1165.

(42) Levine S & R Lowinski, Hyperacute allergic encephalomyelitis, Amer J Path, 1973; 73:247-250.

(43) Munoz JJ et al, Elicitation of experimental encephalomyelitis in mice with aid of pertussigen, Cellular Immunology, 1984; 83(1):92-100.

(44) Iwasa S et al, Swelling of the brain caused by pertussis vaccine: its quantitative determination and responsible factors in the vaccine, Japan J Med Sci Biol, April, 1985; 38(2):53-65.

(45) Jacob J & F Manning, Increased intracranial pressure after diphtheria, tetanus, pertussis immunization, J Dis Child, Feb., 1979; 133:217-218.

(46) Gross TP et al, Bulging fontanelle after immunization with diphtheria-tetanus-pertussis, J Pediatrics, March, 1989;114(3):423-425.

(47) Mathur R & S Kumari, Bulging fontanelle following DPT, Indian Pediatr, June, 1981; 18(6):417-418.

(48) Steinman L et al, Murine model for pertussis vaccine encephalopathy: linkage to H-2, Nature, Oct., 1982; 299(21):738-740.

(49) McCuskey RS et al, Review: the microcirculation during endotoxemia, Cardiovascular Res, Oct., 1996; 32(4):752-763.

(50) An article from this office, "Shaken Baby Syndrome or Vaccine-Induced Encephalitis?," has been accepted for publication. In the meantime, any wishing a copy of a prepublication draft of this article should mail the request with a self-addressed envelope with 66 cents in stamps.

(51) Changes in the Population of Persons with Autism and Pervasive Developmental Disorders in California's Developmental Services, 1987 through 1998, a Report to the Legislature, March 1, 1999, Department of Developmental Services, 1600 North St., Room 240, Sacramento, CA 95814.

(52) -Assessment, Evaluation and Support Unit, Special Education Division, California Department of Education.
- Total Enrollment and Percent of Pupils with Disabilities by Federal Education Programs, New Jersey State Department of Education.
- Illinois State Board of Education Report (8/20/98)
- Rhode Island Department of Elementary and Secondary Education, annual statistical reports.
- Sixteenth through Twentieth Annual Reports to Congress on the implementation of the Individuals with Disabilities Education Act,
http://www.ed.gov/offices/OSERS/OSEP/OSEP94-98AnlRpt/

(53) Consult: http://autism.com/ari/editorials/explosion.html.

(54) Singh V & V Yang, Serological association of measles virus and human herpes virus-6 with brain autoantibodies in autism, Clinical Immunology and Immunopathology, 1998; 88(1):105-108.

(55) Kumar S & SK Miller, Effects of serial passage of Autographa California nuclear poly hedrosis virus in cell culture, Virus Research, 1987; Vol 7:335-349.

(56) Jahnke U et al, Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis, Science, July 19, l985; 29:242-284.

(57) Gupta S et al, Dysregulated immune system in children with autism, beneficial effects of intravenous globulin on autistic features, J of Autism and Developmental Disorders, 1996; 26(4):439-452. (In this article on page 450 it is stated, "We theorize that the high titers of rubella antibody…presented in mothers of children with autism would be transplacentally transferred and may persist for a prolonged period in the child. When such a child gets MMR immunization, rubella antigen may complex with preexisting antibodies, and such complexes might play a role in pathogenesis of autistic features.")

(58) Wakefield AJ et al, Persistent measles virus infection and immunodeficiency in children with autism, ileo-colonic lymphoid nodular hyperplasia and nonspecific colitis, Gut, 1998; 42(Suppl 1):A86.

(59) Wakefield AJ et al, Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, Lancet, Feb. 28, 1998; 351:637-641.

(60) Wakefield AJ et al, Enterocolitis in children with developmental disorders, Amer J Gastroent, Sept., 2000; 95(9):2285-2295.

(61) Looking UP, the Monthly International Autism Newletter, 2000; 2(3):16-21. (This issue of Looking Up gives the full text of Dr. Wakefield's presentation at the Congressional hearings of April 6, 2000)(Address: Looking Up, PO Box 25727, London, SW19 1WF, England; Fax/Tel 020-8542 7702; Email: Looking Up@compuserve.com.)

(62) Buynak et al, Combined live measles, mumps, and rubella virus vaccines, JAMA, 1969; 207:2259-2262.

(63) Minekawa et al, Biken J, 1974; 17:161-167.

(64) Wakefield AJ & Scott Montgomery, Measles, mumps, rubella vaccine: Through a glass darkly, Adverse Drug React Toxicol Rev,19(3), January, 2001:1-19.

(65) Three of the four reviewers who wrote statements supportive of the Wakefield/Montgomery article included Professor Dame Rosalinde Hurley, Professor D W Vere, and A Peter Fletcher.

(66) The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, rhinoconjunctivitis, and atopic eczema, Lancet, 1998; 351:1225-1232.

(67) The Human Ecologist (National HEAL), fall, 1992; 55:6.

(68) Philadelphia Inquirer, Dec. 8, 1994:A22.

(69) Incao, Philip, Supporting Children's Health, Alternative Medicine Digest, Issue 19, pp. 54-59.

(70) Shaneen SO et al, Measles and atopy in Guinea-Bissau, Lancet, June 19, 1996; 347:1792-1796.

(71) Odent MR, Pertussis vaccination and asthma, is there a link? JAMA, 1994; 271:229-231.

(72) Alm JS et al, Atopy in children of families with anthroposophic lifestyle, Lancet, May 1, 1999; 353:1485-1488.

(73) Kemp T et al, Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology, Nov., l997; 8(6):678-680.

(74) Kosecka U et al, Pertussis adjuvant prolongs intestinal hypersensitivity, Int Arch Allergy Immunol, July, 1999; 119(3):205-211.

(75) Terpstra GK, Comparison of vaccination of mice and rats with Haemophilus influenzae and Bordetella pertussis as models of atopy, Clin Exp Pharmacol

(76) Dahlback M et al, The non-specific enhancement of allergy. III. Precipitation of bronchial anaphylactic reactivity in primed rats by injection of alum or B. pertussis vaccine: relation of response capacity to IgE and IgG2a antibody levels, Allergy, May, 1983; 38(4):261-271.

(77) Odelram H et al, Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminum content of the vaccines, Pediatr Allergy Immunol, May, 1994; 5(2):118-123.

(78) Patrizi A et al, Sensitization to thimerosal in atopic children, Contact Dermatitis, Feb., 1999; 40(2):94-97.

(79) Immunobiology, the Immune System in Health and Disease, Charles Janeway, Paul Travers, Mark Walport, Donald Capra, Fourth Edition, North America: Garland Publishing, 19 Union Square West, New York, NY 10003, 1999, Page 393.

(80) Romagnani S, Biology of human TH1 and TH2 cells, J Clin Immunol, 1995; 15(3):121-129.

(81) Refer to reference 79, pages 394-395.

(82) Quagriello V et al, Recombinant human Interleukin-l induces meningitis and blood-brain barrier injury in the rat, J Clin Invest, 1991; 87:1360-1366.

(83) Yamasaki Y, Interleukin-l as a pathogenetic mediator of ischemic brain damage in rats, Stroke, 1995; 26:676-681.

(84) Madara JL & Joan Stafford, Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers, J Clin Invest, Feb., 1989; 83:724-727.

(85) Adams RB et al, IFN-gamma modulation of epithelial barrier function; time course, reversibility, and site of cytokine binding, J Immunol, 1993; 150:2356.

(86) Huynh HK & D katerina, Effects of interferon-gamma on primary culture of human brain microvessel endothelial cells, Am J Pathol, 1993; 142:1265-1278.

(87) Eufemia PD et al, Abnormal intestinal permeability in children with autism, Acta Paediatr, 1996; 85:1076-1079.

(88) Robinson DS, Predominant TH2-like bronchoalveolar T-Lymphocyte population in atopic asthma, New Engl J Med, Jan. 30, 1992; 326:298-304.

(89) Holt PG &PD Sly, Allergic respiratory disease: strategic targets for primary prevention during childhood, Thorax, 1997; 52:1-4.

(90) Refer to reference 77, pages 393-396.

(91) Gupta S et al, Th1 and Th2-like cytokines in CD4+ and CD8+ T cells in autism, J of Neuroimmunol, 1998; 85:106-109.

(92) Hannan KL et al, Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome, Blood Coagulation and Fibrinolysis, 11(7);2000:673-678.

(93) Berg D et al, Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome (APS); an explanatory model and approach to laboratory diagnosis, Blood Coag Fibrinolysis, 10; 1999:435-438.

(94) Lederberg L, Letter-to-the-Editor, Science, October 20, 1967, p 313.

(95) Montinari MG et al, Diagnostica role of immunogenetics in post-vaccine diseases of the central nervous system: preliminary results, Meditarranean J Surg & Med, 1996; 2:69-72.

(96) Urnovitz HB et al, RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11.2, Clin Diagn Lab Immunol, May, 1999; 6(3):330-335.

(97) Garth L et al, The anthrax vaccine controversy - questions about its efficacy, safety and strategy, Medical Sentinel, May-June, 2000; 5(3):97-101.

(98) Available through: HTTP://www.vaccinesafety.edu*/thi-table.htm

(99) Halsey NA, Limiting infant exposure to thimerosal in vaccines and other sources, JAMA, 282(18);November 10, 1999:1763-1766.

(100) Leong CCW, Naweed IS, Lorscheiderae FL, Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury, NeuroReport, Accepted for publication Dec. 21, 2000; 12(4):0733-0737.

(101) Galazka A, Kardymowicz BA, Complications and reactions after vaccination with pertussis, Epidemiological Review, 1972; 26:411-424.

If you find this newsletter interesting and valuable, help support it by recommending it to some friends by using this button.

Return to Table of Contents #227

©Copyright 1997-2001 by Joseph M. Mercola, DO. All Rights Reserved. This content may be copied in full, with copyright; contact; creation; and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Mercola is required.

Disclaimer - Newsletters are based upon the opinions of Dr. Mercola. They are not intended to replace a one-on-one relationship with a qualified health care professional and they are not intended as medical advice. They are intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional.